Abstract
A significant clinical problem is patients presenting with exercise-limiting dyspnoea, sometimes with associated chest pain, in the absence of detectable left ventricular (LV) systolic dysfunction, coronary artery disease, or lung disease. Often the patients are older, female, and have isolated basal septal hypertrophy (BSH), frequently on a background of mild hypertension. The topic of breathlessness in patients with clinical heart failure, but who have a normal ejection fraction (HFNEF) has attracted significant controversy over the past few years. This review aims to analyse the literature on BSH, identify the possible associations between BSH and HFNEF, and consequently explore possible pathophysiological mechanisms whereby clinical symptoms are experienced.
Keywords: Basal septal hypertrophy, diastolic dysfunction, HFNEF, outflow tract obstruction.
Call for Papers in Thematic Issues
Advances in Managing Cardiogenic Shock and the Value of Percutaneous Mechanical Circulatory Support.
Despite the advances in cardiology, the outcomes of patients with cardiogenic shock remain poor. There is an increasing interest and use of mechanical circulatory support for patients with cardiogenic shock. Additionally, the complexity of coronary interventions has increased during the last decade with the potential of treating more high-risk patients ...read more
Artificial Intelligence (AI) in cardiovascular disease
Artificial Intelligence (AI) in cardiovascular disease is an emerging interdisciplinary field that integrates advanced technologies to improve patient care. The current AI landscape faces significant challenges, including the complexity of diagnosing and treating these conditions. Recent studies have shown promising results in the use of AI for early detection, diagnosis, ...read more
Chronic Disease Self-Management for Heart Failure – A Mini Review into Performance Gaps
Chronic disease self-management (CDSM)is a vital component of chronic disease management. There remain several important deficits in this concept. Its benefit are clear, many chronic diseases such as hypertension, diabetes, asthma, rheumatology syndromes have shown benefit in quality of life and quantitative measures of outcomes. Yet, in congestive heart failure ...read more
The era of cardiac medication and implantable devices therapy in heart failure treatment continues
The heart failure (HF) remains a serious public health problem and affects 64 million people worldwide. Although advances in medical therapy and device assistance have significantly improved HF outcomes, the implications of HF are still dramatic. In recent years, innovative developments have been made in HF treatment management, based on ...read more
Related Books
Blood Oxidant Ties: The Evolving Concepts in Myocardial Injury and Cardiovascular Disease
Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives
Herbal Medicine: Back to the Future
Cardiac Care and COVID-19: Perspectives in Medical Practice
Nanomedicinal Approaches Towards Cardiovascular Disease
Herbal Medicine: Back to the Future
19
